Imricor’s VISABL-AFL Trial for US FDA Approval Commences at Cardiovascular Institute of South Paris

Contributed by: Business Wire

Logo

Images

VISABL-AFL Procedure at ICPS (Photo: Business Wire)

Imricor’s NorthStar Mapping System being used in the VISABL-AFL Procedure (Photo: Business Wire)

Business Wire embedded0

Tags

Software

General Health

Medical Devices

Technology

Hospitals

Health Technology

Clinical Trials

Surgery

Cardiology

Biotechnology

FDA

Health

iCMR cardiac ablation products

More Like This

Imricor VISABL-VT Clinical Trial Enrollment

Imricor Commences VISABL-VT Trial

MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System

PR Newswire associated0

Adagio Medical Announces CE Mark approval of VT Cryoablation System, Plans for Immediate Commercialization in Select European Centers

AtriCure Receives CE-Mark for the EnCompass® Clamp

PR Newswire associated0

Adagio Medical Announces Initiation and First Procedure in FULCRUM-VT Trial, Starting The Process For Bringing Ultra-Low Temperature Cryoablation for Ventricular Arrhythmias to US Market

PR Newswire associated0

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

PR Newswire associated0

PulseCath Achieves MDR CE Certification for iVAC 2L, Paving the Way for Complex High-Risk Percutaneous Coronary Interventions

PR Newswire associated0

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform